197.93
-2.04(-1.02%)
Currency In USD
| Previous Close | 199.97 |
| Open | 197.22 |
| Day High | 200.08 |
| Day Low | 192.52 |
| 52-Week High | 212.98 |
| 52-Week Low | 122.8 |
| Volume | 261,802 |
| Average Volume | 321,939 |
| Market Cap | 5.73B |
| PE | 29.67 |
| EPS | 6.67 |
| Moving Average 50 Days | 174.55 |
| Moving Average 200 Days | 159.76 |
| Change | -2.04 |
If you invested $1000 in Krystal Biotech, Inc. (KRYS) since IPO date, it would be worth $18,602.44 as of November 10, 2025 at a share price of $197.93. Whereas If you bought $1000 worth of Krystal Biotech, Inc. (KRYS) shares 5 years ago, it would be worth $4,748.8 as of November 10, 2025 at a share price of $197.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025
GlobeNewswire Inc.
Oct 21, 2025 12:00 PM GMT
PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to the open of U.S. markets. The Comp
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the genetically modified, non-re
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
GlobeNewswire Inc.
Sep 15, 2025 12:00 PM GMT
Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United Sta